<DOC>
	<DOC>NCT01011218</DOC>
	<brief_summary>Primary Objective: 1. To provide preliminary data on the effects of armodafinil and Brief Behavioral Therapy for Insomnia (BBT-I) (alone or in combination) on insomnia in breast cancer patients receiving chemotherapy. Secondary Objectives: 1. To provide preliminary data on the influence of armodafinil and BBT-I (alone or in combination) on cancer-related fatigue (CRF) in breast cancer patients receiving chemotherapy. 2. To provide preliminary data on the influence of armodafinil and BBT-I (alone or in combination) on QOL in breast cancer patients receiving chemotherapy. 3. To provide preliminary data on influence of armodafinil and BBT-I (alone or in combination) on endocrine and inflammatory physiological markers (measured by cortisol and inflammatory cytokines markers)</brief_summary>
	<brief_title>Management of Insomnia in Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Be scheduled for planned cancer treatment with chemotherapy or biologics, such as Herceptin (prior chemotherapy and diagnosis of metastatic breast are allowed) Have at least 6 weeks of treatment remaining Be at least 21 years old Be able to swallow medication Exhibit onset or worsening of problems falling or staying asleep Have ever taken armodafinil or modafinil Have an unstable medical or psychiatric illness (Axis I current or within the last 5 years) Have a history of or uncontrolled cardiac disease, hypertension, severe headaches, glaucoma, or seizures Have taken a psychostimulant medication within the past 28 days Be currently pregnant or nursing Have a history of substance abuse or meet criteria for current alcohol abuse or dependence Have a selfreported history of chronic, preexisting insomnia, sleep apnea, or RLS syndrome Have taken sleep medication daily for the last 28 days continuously Have severe hepatic impairment Be taking antiseizure medications</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>quality of life</keyword>
</DOC>